Brief: Guardant Health Announced the results of the Serena-6 Phase III Trial
02/06/2025 13:40
June 2 (Reuters) - Guardant Health Inc GH.O: SERENA-6 PHASE III TRIAL DEMONSTRATES CLINICAL VALUE OF GUARDANT360 CDX TEST TO DETECT EMERGENCE OF ENDOCRINE RESISTANCE AND INFORM A SWITCH IN THERAPY BEFORE RADIOLOGICAL DISEASE PROGRESSION IN ADVANCED BREAST CANCER Source text: ID:nBwMTNgRa Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsU.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
U.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte